Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2013 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. and The Leukemia & Lymphoma Society Announce Collaboration to Accelerate the Development of SL-401 in Hematologic Cancers and Increase Awareness of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NEW YORK, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) and The Leukemia & Lymphoma Society® (LLS) today announced their collaboration to accelerate the...
September 25, 2013 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Oral Presentation of SL-401, a Clinical-Stage Targeted Therapy, Demonstrating Notable Preclinical Activity in an Additional Indication, Chronic Myeloid Leukemia (CML), at the 15th International Conference on CML

NEW YORK, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that SL-401, which is entering pivotal clinical trials in blastic plasmacytoid dendritic cell...
September 19, 2013 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the Aegis Capital Corporation 2013 Healthcare Conference

NEW YORK, Sept. 19, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the at the Aegis Capital Corporation...
September 04, 2013 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference

NEW YORK, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Chief Executive Officer, will present at the 15th Annual Rodman &...
August 07, 2013 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. to Present at the 2013 Wedbush Life Sciences Conference

NEW YORK, Aug. 7, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Chief Executive Officer, will present at the 2013 Wedbush Life Sciences...
July 03, 2013 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. to Present at the JMP Securities Healthcare Conference

NEW YORK, July 3, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Chief Executive Officer, will present at the 8th Annual JMP Securities...
July 01, 2013 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. Added to Russell 3000(R) Index

NEW YORK, July 1, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem...
June 10, 2013 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics' SL-401 Receives Orphan Drug Designation for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NEW YORK, June 10, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) today announced that SL-401 has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA)...
May 31, 2013 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference

NEW YORK, May 31, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Chief Executive Officer, will present at the Jefferies 2013 Global...
May 30, 2013 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Presentations at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting

NEW YORK, May 30, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) today announced that SL-401 clinical results in patients with acute myeloid leukemia (AML) and blastic plasmacytoid...